These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 21081251)

  • 1. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
    D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
    Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect.
    D'Alto M; Vizza CD; Romeo E; Badagliacca R; Santoro G; Poscia R; Sarubbi B; Mancone M; Argiento P; Ferrante F; Russo MG; Fedele F; Calabrò R
    Heart; 2007 May; 93(5):621-5. PubMed ID: 17135220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
    Garg N; Sharma MK; Sinha N
    Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of sildenafil in Eisenmenger's syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study.
    Garg N; Tripathy N; Sinha N
    Cardiol Young; 2011 Dec; 21(6):631-8. PubMed ID: 21729508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study.
    Zhang ZN; Jiang X; Zhang R; Li XL; Wu BX; Zhao QH; Wang Y; Dai LZ; Pan L; Gomberg-Maitland M; Jing ZC
    Heart; 2011 Nov; 97(22):1876-81. PubMed ID: 21948962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial.
    Iversen K; Jensen AS; Jensen TV; Vejlstrup NG; Søndergaard L
    Eur Heart J; 2010 May; 31(9):1124-31. PubMed ID: 20202971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K; Jakrapanichakul D; Sompradikul S
    J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pulmonary vasodilator therapy on ventilatory efficiency during exercise in adults with Eisenmenger syndrome.
    Yang-Ting S; Aboulhosn J; Sun XG; Child JS; Sietsema KE
    Congenit Heart Dis; 2011; 6(2):139-46. PubMed ID: 21418531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
    Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
    Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preliminary study on the efficacy and safety of oral sildenafil in pulmonary arterial hypertension in China].
    Xiong CM; He JG; Lu XL; Shan GL; Wu BX; Zhu XY; Wu GH; Zeng XF; Guo T; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Tian HY; Li WM; Zhang DZ; Zhang C; Li MT; Liu HM; Guo YJ; Shen JY; Zhang WJ; Liu S; Zhou DX; Bao CD; Huang SA; Chen JY; Wu WF; Huang K; Li CL; Wang LH; He B
    Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(6):370-4. PubMed ID: 21418907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.
    D'Alto M; Romeo E; Argiento P; Santoro G; Sarubbi B; Gaio G; Mélot C; Russo MG; Naeije R; Calabrò R
    Heart; 2010 Sep; 96(18):1475-9. PubMed ID: 20668108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.
    D'Alto M; Romeo E; Argiento P; D'Andrea A; Sarubbi B; Correra A; Scognamiglio G; Papa S; Bossone E; Calabrò R; Vizza CD; Russo MG
    Int J Cardiol; 2013 Apr; 164(3):323-6. PubMed ID: 21802156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of bosentan in adults with Eisenmenger physiology.
    Gatzoulis MA; Rogers P; Li W; Harries C; Cramer D; Ward S; Mikhail GW; Gibbs JS
    Int J Cardiol; 2005 Jan; 98(1):147-51. PubMed ID: 15676179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
    Douwes JM; Roofthooft MT; Van Loon RL; Ploegstra MJ; Bartelds B; Hillege HL; Berger RM
    Heart; 2014 Feb; 100(3):224-30. PubMed ID: 24390161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease.
    Baptista R; Castro G; da Silva AM; Monteiro P; Providência LA
    Rev Port Cardiol; 2013 Feb; 32(2):123-9. PubMed ID: 23351920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.